hepatology Archives - Page 2 of 2 -

France’s Genfit has said its elafibranor drug as a treatment for non-alcoholic steatohepatitis (NASH) was unable to improve

Genfit abandons late-stage trial of NASH drug elafibranor

https://pharmaphorum.com/news/genfit-abandons-late-stage-trial-of-nash-drug-elafibranor/

News/ News/ R&D

Another NASH setback as CymaBay drops seladelpar

Phil Taylor CymaBay Therapeutics, hepatology, NASH 0 Comment

CymaBay Therapeutics has scrapped two mid-stage trials of seladelpar in non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC),

Another NASH setback as CymaBay drops seladelpar

https://pharmaphorum.com/news/another-nash-setback-as-cymabay-drops-seladelpar/

News/ News/ R&D

Novartis takes $80M punt on early-stage NASH drug from Pliant

Phil Taylor hepatology, licensing, NASH, Novartis, Pliant Therapeutics 0 Comment

Novartis has added another non-alcoholic steatohepatitis (NASH) drug candidate to its pipeline via an $80 million licensing deal

Novartis takes $80M punt on early-stage NASH drug from Pliant

https://pharmaphorum.com/news/novartis-takes-80m-punt-on-early-stage-nash-drug-from-pliant/

News/ R&D/ Rare diseases

Alnylam hopes for 2018 filing for RNAi liver disease drug

Richard Staines Alnylam, Biotech, hepatology, Ionis, RNAi 0 Comment

Alnylam is hoping to file a second RNA interference (RNAi) drug with the FDA by the end of 2018

Alnylam hopes for 2018 filing for RNAi liver disease drug

https://pharmaphorum.com/news/alnylam-hopes-2018-filing-rnai-liver-disease-drug/

News/ UK & Europe

Novo Nordisk board member quits over NASH conflict of interest

Richard Staines hepatology, NASH, Novo Nordisk, R&D 0 Comment

Mary Szela has quit to avoid a conflict of interest.

Novo Nordisk board member quits over NASH conflict of interest

https://pharmaphorum.com/news/novo-nordisk-board-member-quits-nash/

M&A/ News

Can Gilead find another Pharmasset in 2017?

Richard Staines Gilead, hepatitis C, hepatology, infectious diseases, M&A 0 Comment

Company needs to make acquisition to grow, admits CEO.

Can Gilead find another Pharmasset in 2017?

https://pharmaphorum.com/news/can-gilead-find-another-pharmasset-2017/

Trending

hepatology

Login